Rwanda Recalls French-Manufactured Aspirin Over Quality Concerns

The Rwanda Food and Drugs Authority (Rwanda FDA) has announced a recall.

This affects batch No. B6224 of Aspirine Vitamin C 330mg/200mg effervescent tablets. The product is made by Union de pharmacologie scientifique appliquée (UPSA), a French pharmaceutical group.

The recall is due to quality concerns. The affected batch was produced in September 2024 and expires in August 2026.

On April 23, Rwanda FDA issued a statement about the issue. Investigations revealed that the medicine changed color from white to brown. This change compromises the product's quality standards.

Rwanda FDA has ordered an immediate halt to distribution and dispensing of this batch.

Importers, distributors, and health facilities must return the recalled products to suppliers. They need to report back to Rwanda FDA within 10 working days of the notice.

Reports should include quantities imported, distributed, returned, and remaining stock.

The public is advised not to use any products from this batch. For more guidance, stakeholders can contact Rwanda FDA directly.